EDINBURGH, UK – December 16, 2024
Concinnity Genetics, a biotech spinout from the University of Edinburgh, has raised £3 million in seed funding to revolutionize gene therapy safety. The funding round was led by Eos Advisory with support from Scottish Enterprise, Old College Capital, and Maven Capital Partners.
Addressing Gene Therapy Safety with Precision Control
Concinnity’s innovative platform combines synthetic biology and AI to create RNA-based control systems that enhance the safety of gene therapies. These systems allow precise regulation of therapies after administration, enabling them to mitigate side effects dynamically.
Co-founded by Jessica Birt and Dr. Matthew Dale, the company has been described as a pioneer in gene control technology. The platform offers unprecedented reliability, designed to address a critical unmet need in the cell and gene therapy market.
Funding Allocation
The newly secured funding will enable Concinnity to:
• Spin out operations from the UKRI UK Centre for Mammalian Synthetic Biology.
• Launch three new programs targeting key cell and gene therapy applications.
• Continue refining existing systems to generate essential commercial validation data.
Transformative Potential in Biopharma
Concinnity’s synthetic control systems are agnostic to therapeutic types, allowing widespread applicability across various gene therapy areas. Unlike traditional methods, Concinnity’s technology is engineered to respond to specific input signals, offering tailored safety mechanisms for therapies.
Jessica Birt, CEO, emphasized the company’s vision:
“Our ambition is to be the go-to partner for gene control, making cell and gene therapies as safe as possible. This commitment from our investors highlights the transformative potential of our technology.”
Support from Key Stakeholders
• Andrew McNeill, Managing Partner at Eos, described Concinnity’s approach as the “holy grail” for improving the effectiveness and safety of emerging gene therapies.
• Dr. Andrea Taylor, CEO of Edinburgh Innovations, praised the company’s potential to catalyze advanced therapeutic solutions, aligning with Scotland’s growing reputation as a life sciences hub.
• Kerry Sharp, Director at Scottish Enterprise, added: “Concinnity exemplifies the innovation driving Scotland’s biotech industry forward, and we are proud to support its international growth.”
A Future in Safe Gene Therapy
Concinnity is poised to establish a significant presence in the cell and gene therapy market, ensuring therapies are safer and more effective. With its robust funding and innovative technology, the company aims to drive forward the next generation of gene-based treatments.
For more information, visit Concinnity Genetics.
Media Contact:
Email: [email protected]
Location: Edinburgh, UK
